Research Papers
This database includes peer-reviewed publications authored by TB Alliance staff. Use the tags on the left to filter by subject, or search for a particular author or term using the search bar.
Tag: Pretomanid/PA-824
Displaying 44 papers
Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosis
Publication: PLOS Global Public Health
11/2022
Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis
Publication: New England Journal of Medicine
9/2022
Assessment of the Carcinogenic Potential of Pretomanid in Transgenic Tg.rasH2 Mice
Publication: International Journal of Toxicity
7/2022
Toxicity and toxicokinetic assessment of an anti-tubercular drug pretomanid in cynomolgus monkeys
Publication: Toxicology Reports
4/2022
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid
Publication: Antimicrobial Chemotherapy
3/2022
Pretomanid with Bedaquiline and Linezolid for Drug Resistant TB: A Comparison of Prospective Cohorts
4/2021
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
Publication: International Journal of Tuberculosis and Lung Disease
3/2021
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
Publication: The New England Journal of Medicine
3/2020
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial
Publication: The Lancet Respiratory Medicine
11/2019
Population Pharmacokinetics of the Antituberculosis Agent Pretomanid
Publication: Antimicrobial Agents and Chemotheraphy
8/2019
Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis
Publication: Antimicrobial Agents and Chemotheraphy
7/2019
Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
Publication: Antimicrobial Agents and Chemotheraphy
4/2019
Antitubercular nitroimidazoles revisited: synthesis and activity of the authentic 3-nitro isomer of pretomanid
Publication: ACS Medicinal Chemistry Letters
12/2017
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant...
Publication: Dawson R, Diacon AH, Everitt D, et. al. Efficiency and safety of.... Lancet. 2015 May 2;385(9979):1738-47. doi: 10.1016/S0140-6736(14)62002-X.
5/2015
Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline
Publication: Diacon AH, Dawson R, von Groote-Bidlingmaier F, et. al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med. 2015 Apr 15;191(8):943-53. doi: 10.1164/rccm.201410-1801OC.
4/2015
Contribution of the Nitroimidazoles PA-824 and TBA-354 to the Activity of Novel Regimens in Murine Models of Tuberculosis
Publication: Tasneen R, Williams K, Amoabeng O, Minkowski A, Mdluli KE, Upton AM, Nuermberger EL. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrob Agents Chemother. 2015 Jan;59(1):129
1/2015